Drug Type Small molecule drug |
Synonyms Flupentixol and Melitracen, 盐酸氟哌噻吨/盐酸美利曲辛, Deanxit + [1] |
Target |
Action antagonists |
Mechanism DRDs antagonists(Dopamine receptors antagonists), Monoamine reuptake inhibitor |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
Molecular FormulaC52H67F3N4O2S |
InChIKeyMKWJDUAOJQMMSS-UHFFFAOYSA-N |
CAS Registry214556-54-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Flupenthixol Hydrochloride/Melitracen Hydrochloride | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anxiety Disorders | China | - | - |
Depressive Disorder | China | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Opioid-Related Disorders | Phase 3 | China | 14 Oct 2014 |
Not Applicable | 160 | Control group | dcaoinjstn(swggfqhhog) = jqsskjiqfp qwmttnsusf (pzgseohppa ) | - | 15 Jun 2019 | ||
dcaoinjstn(swggfqhhog) = ytxofrptpx qwmttnsusf (pzgseohppa ) | |||||||
Phase 4 | 262 | wpixorissf(hueeonmqks) = jcylhrivyk wjuporerta (ihwcnzobsl, fvceehfwhm - tsxosvbmug) View more | - | 23 Feb 2015 |